Mirikizumab (Omvoh®) for the Treatment of Adult Patients with Moderately to Severely Active Crohn’s Disease
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for mirikizumab (Omvoh) for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.